Opin vísindi

Fletta eftir höfundi "Agnarsson, Bjarni A."

Fletta eftir höfundi "Agnarsson, Bjarni A."

Röðun: Raða: Niðurstöður:

  • Icon
    The BRCA1 c.4096+3A>G Variant Displays Classical Characteristics of Pathogenic BRCA1 Mutations in Hereditary Breast and Ovarian Cancers, But Still Allows Homozygous Viability 
    Arason, Adalgeir; Agnarsson, Bjarni A.; Jóhannesdóttir, Gudrún; Jóhannsson, Óskar Þór; Hilmarsdóttir, Bylgja; Reynisdóttir, Inga; Barkardottir, Rosa Bjork (MDPI AG, 2019-11-01)
    Mutations in BRCA1 result in predisposal to breast and ovarian cancers, but many variants exist with unknown clinical significance (VUS). One is BRCA1 c.4096+3A>G, which affects production of the full-length BRCA1 transcript, while augmenting transcripts ...
  • Icon
    Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry : Proposal for a bone marrow quality index 
    Óskarsson, Jón Þórir; Rögnvaldsson, Sæmundur; Thorsteinsdottir, Sigrun; Aspelund, Thor; Gunnarsson, Steinar Bragi; Hákonardóttir, Guðlaug Katrín; Sigurðardóttir, Guðrún Ásta; Þórðardóttir, Ásdís Rósa; Gíslason, Gauti Kjartan; Ólafsson, Andri; Sigurðsson, Jón Kristinn; Eyþórsson, Elías; Jónsson, Ásbjörn; Viðarsson, Brynjar; Önundarson, Páll Torfi; Agnarsson, Bjarni A.; Pálmason, Róbert; Sigurðardóttir, Margrét; Þorsteinsdóttir, Ingunn; Ólafsson, Ísleifur; Harding, Stephen; Flores-Montero, Juan; Orfao, Alberto; Durie, Brian G.M.; Love, Thorvardur Jon; Kristinsson, Sigurdur Yngvi (2023-12-01)
    Hemodilution of bone marrow (BM) aspirates is a limitation of multiparameter flow cytometry (MFC) in plasma cell disorders. There is a need for a validated approach for assessing sample quality and the distribution of non-plasma cell BM populations by ...
  • Icon
    The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer 
    Figlioli, Gisella; Agnarsson, Bjarni A.; Barkardottir, Rosa Bjork (Springer Science and Business Media LLC, 2019-11-01)
    Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has ...
  • Icon
    Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA 
    Gudmundsson, Julius; Sigurðsson, Jón K.; Stefánsdóttir, Lilja; Agnarsson, Bjarni A.; Ísaksson, Helgi J.; Stefánsson, Ólafur A.; Guðjónsson, Sigurjón Axel; Gudbjartsson, Daniel; Másson, Gísli; Frigge, Michael L.; Stacey, Simon N.; sulem, patrick; Halldorsson, Gisli; Tragante, Vinicius; Holm, Hilma; Eyjólfsson, Guðmundur I.; Sigurðardóttir, Ólöf; Olafsson, Isleifur; Jónsson, Þorvaldur; Jónsson, Eirikur; Barkardottir, Rosa Bjork; Hilmarsson, Rafn; Asselbergs, Folkert W.; Geirsson, Guðmundur; Thorsteinsdottir, Unnur; Rafnar, Thorunn; Thorleifsson, Gudmar; Stefansson, Kari (Springer Science and Business Media LLC, 2018-11-08)
    Benign prostatic hyperplasia and associated lower urinary tract symptoms (BPH/LUTS) are common conditions affecting the majority of elderly males. Here we report the results of a genome-wide association study of symptomatic BPH/LUTS in 20,621 patients ...
  • Icon
    High expression of the vacuole membrane protein 1 (VMP1) is a potential marker of poor prognosis in HER2 positive breast cancer 
    Amirfallah, Arsalan; Arason, Adalgeir; Einarsson, Hjörleifur; Guðmundsdóttir, Eydís Þórunn; Freysteinsdóttir, Edda Sigríður; Ólafsdóttir, Kristrún Auður; Jóhannsson, Óskar Þór; Agnarsson, Bjarni A.; Barkardottir, Rosa Bjork; Reynisdottir, Inga (Public Library of Science (PLoS), 2019-08-23)
    Background: Fusion genes result from genomic structural changes, which can lead to alterations in gene expression that supports tumor development. The aim of the study was to use fusion genes as a tool to identify new breast cancer (BC) genes with a ...
  • Icon
    Iceland screens, treats, or prevents multiple myeloma (iStopMM) : a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies 
    Rögnvaldsson, Sæmundur; Love, Thorvardur Jon; Thorsteinsdottir, Sigrun; Reed, Elín Ruth; Óskarsson, Jón Þórir; Pétursdóttir, Íris; Sigurðardóttir, Guðrún Ásta; Viðarsson, Brynjar; Önundarson, Páll Torfi; Agnarsson, Bjarni A.; Þorsteinsdóttir, Ingunn; Ólafsson, Ísleifur; Þórðardóttir, Ásdís Rósa; Eyþórsson, Elías; Jónsson, Ásbjörn; Björnsson, Andri S.; Gunnarsson, Gunnar Þór; Pálsson, Runólfur; Indriðason, Ólafur Skúli; Gíslason, Gauti Kjartan; Ólafsson, Andri; Hákonardóttir, Guðlaug Katrín; Brinkhuis, Manje; Halldórsdóttir, Sara Lovísa; Ásgeirsdóttir, Tinna Laufey; Steingrímsdóttir, Hlíf; Danielsen, Ragnar; Dröfn Wessman, Inga; Kampanis, Petros; Hulcrantz, Malin; Durie, Brian G.M.; Harding, Stephen; Landgren, Ola; Kristinsson, Sigurður Yngvi (2021-05-17)
    Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland Screens, Treats, or Prevents Multiple Myeloma ...
  • Icon
    In situ breast cancer incidence patterns in Iceland and differences in ductal carcinoma in situ treatment compared to Sweden 
    Agustsson, Arnar S.; Birgisson, Helgi; Agnarsson, Bjarni A.; Jonsson, Thorvaldur; Stefansdottir, Hrefna; Wärnberg, Fredrik; Lambe, Mats; Tryggvadottir, Laufey; Sverrisdottir, Asgerdur (2020-12-01)
    The purpose was to review the incidence of in situ carcinoma in Iceland after initiating population-based mammography screening in 1987 and to compare management of ductal carcinoma in situ (DCIS) between Iceland and the Uppsala–Örebro region (UÖR) in ...